可溶性组织因子突变体的基因构建、表达和性质

血浆中组织因子 (TF)的过量表达与许多病理过程密切相关。TF抑制物有可能防治这些疾病。设计了两种可溶性组织因子 (sTF)的突变体 (MCsTF和MFsTF) ,突变了协同催化的功能域 ,保留与因子VII/VIIa结合的功能域 ,使突变体竞争性抑制野生型TF的功能。用PCR的方法 ,对可溶性组织因子cDNA基因进行了点突变 ,并实现了在大肠杆菌中高效表达。rsTF、rMCsTF和rMFsTF的促凝活性研究表明 ,rMFsTF的激活X因子活性和促凝血作用相当于rsTF的 10 % ,而rMCsTF几乎完全失去了激活X因子活性和促凝血作用。rMCsTF和rMFsTF与VII/VIIa因子形成复合物对激活X因子的催化特异常数 (kcat/Km)分别是FVII/VIIa·rsTF的 2 .0 %和 3.7% ,也说明突变体与VII/VIIa形成的复合物对激活X因子催化活性显著降低。rMCsTF和rMFsTF对rsTF活性抑制动力学研究及体外活性研究表明 ,两种突变体均有抑制rsTF活性和抑制兔脑粉的促凝活性作用 ,抑制作用呈量效关系

Molecular Cloning, Expression and Characterization of the Clones Encoding Soluble TF Mutants

Tissue factor (TF) plays an important role in the pathogenesis of atherosclerotic, sepsis and disseminated intravascular coagulation (DIC). TF pathway is therefore an attractive therapeutic target in a number of disease states. Here two TF mutants were developed and named MCsTF and MFsTF, in which the amino acids of active sites were mutated. Both of them were expressed in E.coli and used to inhibit TF pathway through competitive FVII/VIIa binding with TF. The results indicated that rMCsTF almost lost all activities of FX activation and procoagulation, and rMFsTF lost 90% activity. The specific catalytic constant (k cat/K m) of FX activation by the complex formed by FVIIa with rMCsTF or rMFsTF were 2.0% and 3.7%, respectively, compared to that of rsTF. The inhibition effects of the mutants were studied in vitro, and it appeared that the prothrombin time were prolonged in a dose-dependent manner. Therefore, these mutants of TF may become new kind of specific inhibitors of TF pathway, as a promising drug for the treatment of patients with over- expression of TF.